The Pharmacokinetics (PK) of ADC therapeutics typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules. This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex. 

In this webinar, Dr. Apgar will present how quantitative systems pharmacology modeling approaches provide biological insights into the impact of drug-to-antibody ratio and the resulting changes in molecular properties on overall PK and relative payload disposition as observed in preclinical and clinical studies.

This webinar is ideal for scientists interested in how computational models can be used to design novel ADCs and to optimize the discovery and development of existing ADCs.

Featured Speaker:

Joshua Apgar, PhD
Co-Founder and CSO
Applied BioMath

Before co-founding Applied BioMath, Dr. Apgar was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. Josh holds a PhD from MIT in Biological Engineering where he worked on experiment design for Systems Biology, focusing on the identification of tractable experiments that could allow for the estimation of unknown parameters and reveal complex mechanisms in signal transduction networks.

NOW AVAILABLE ON-DEMAND

Register now for this webinar